Molecular Analysis for Gastro-Esophageal Cancer: Multicenter Discrete Choice Experiment (MAGECmultiDiCE)

February 14, 2026 updated by: Stijn Vanstraelen, KU Leuven

The goal of this survey is to investigate the participants' preference for a specific screening/diagnostic tool to detect and assess gastro-esophageal cancer.

The main question it aims to answer are:

  • Which diagnostic modality is preferred by patients and the general population?
  • Which features of the diagnostic test are most detrimental in the decision-making for one or the other modality?
  • Are geographical differences present in regard to the preference for a diagnostic modality?

Participants will be asked to complete a survey of 20-25min, including a brief intake regarding their socio-economic status. This approach will allow us to correct for confounding factors.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

2200

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  1. Individuals >18yo to 75yo (upper age limit of Barrett's surveillance)
  2. Access to computer or smartphone
  3. Clear understanding of available languages of the experiment (English, French, Dutch, Spanish, German, Chinese, Japanese)

Exclusion Criteria:

  1. Individuals less than 18yo and more than 75yo
  2. Incarcerated individuals

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Survey participants
Participants who will complete a survey investigating their preference for diagnosis and assessment of gastro-esophageal cancer
Other: Survey
Discrete choice survey

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The rate of contribution of diagnostic features to the preference of participants
Time Frame: 2 years
A part-worth analysis, expressed as percentage, from a discrete choice experiment (questionnaire) will assess the features that are most important to the participants
2 years
The percentage differences in preference of participants between geographical regions
Time Frame: 2 years
Differences in preferences will be compared between different geographical regions using chi-squared or McNemar's test
2 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Assess the rate patient-level demographics influence the importance of a test feature, expressed as an odds ratio
Time Frame: 2 years
Assess the influence of demographic characteristics on the decision-making process using a multivariable logistic regression model, providing odds ratios.
2 years
Assess the rate of trade-off demonstrated as odds ratio between cancer-related mortality reduction and costs
Time Frame: 2 years
Based on an anticipated cancer detection and cost, we will assess the willingness-to-pay using a multivariable logistic regression, providing odds ratios.
2 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

KU Leuven

Investigators

  • Principal Investigator: Stijn Vanstraelen, MD, UZ Leuven
  • Principal Investigator: Philippe Nafteux, MD, PhD, UZ Leuven

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 1, 2024

Primary Completion (Estimated)

August 1, 2026

Study Completion (Estimated)

August 1, 2026

Study Registration Dates

First Submitted

March 23, 2024

First Submitted That Met QC Criteria

March 28, 2024

First Posted (Actual)

April 3, 2024

Study Record Updates

Last Update Posted (Actual)

February 18, 2026

Last Update Submitted That Met QC Criteria

February 14, 2026

Last Verified

February 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • s68670

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Data will be made available upon reasonable request with the principal investigator

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • ANALYTIC_CODE
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Gastric Cancer

Clinical Trials on Survey

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ecuador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe